Butyrate, Valerate, and Niacin Ameliorate Anaphylaxis by Suppressing IgE-Dependent Mast Cell Activation: Roles of GPR109A, PGE2, and Epigenetic Regulation
The Journal of Immunology · 2024
DOI: 10.4049/jimmunol.2300188 ↗Kurz gefasst
Fachartikel in der Zeitschrift The Journal of Immunology, 2024. Verfasst von Kazuki Nagata und 15 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biological Science and Technology, Faculty of Advanced Engineering, Tokyo University of Science, Niijuku, Katsushika-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Anaphylaxis, Niacin. Die Arbeit wurde bisher 35-mal zitiert (Crossref) und nennt 52 Literaturangaben. Gefördert von: MEXT | Japan Society for the Promotion of Science (JSPS).
Abstract (Originalsprache)
Short-chain fatty acids (SCFAs) are produced by the intestinal microbiota during the fermentation of dietary fibers as secondary metabolites. Several recent studies reported that SCFAs modulate the development and function of immune-related cells. However, the molecular mechanisms by which SCFAs regulate mast cells (MCs) remain unclear. In the current study, we analyzed the function and gene expression of mouse MCs in the presence of SCFAs in vitro and in vivo. We found that the oral administration of valerate or butyrate ameliorated passive systemic anaphylaxis and passive cutaneous anaphylaxis in mice. The majority of SCFAs, particularly propionate, butyrate, valerate, and isovalerate, suppressed the IgE-mediated degranulation of bone marrow–derived MCs, which were eliminated by the Gi protein inhibitor pertussis toxin and by the knockdown of Gpr109a. A treatment with the HDAC inhibitor trichostatin A also suppressed IgE-mediated MC activation and reduced the surface expression level of FcεRI on MCs. Acetylsalicylic acid and indomethacin attenuated the suppressive effects of SCFAs on degranulation. The degranulation degree was significantly reduced by PGE2 but not by PGD2. Furthermore, SCFAs enhanced PGE2 release from stimulated MCs. The SCFA-mediated amelioration of anaphylaxis was exacerbated by COX inhibitors and an EP3 antagonist, but not by an EP4 antagonist. The administration of niacin, a ligand of GPR109A, alleviated the symptoms of passive cutaneous anaphylaxis, which was inhibited by cyclooxygenase inhibitors and the EP3 antagonist. We conclude that SCFAs suppress IgE-mediated activation of MCs in vivo and in vitro involving GPR109A, PGE2, and epigenetic regulation.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Biological Science and Technology, Faculty of Advanced Engineering, Tokyo University of Science, Niijuku, Katsushika-ku, Tokyo, Japan.
ORCID-Profile: Kazuki Nagata, Ryosuke Miura, Yuki Goto, Naoto Ito, Takuya Yashiro, Chiharu Nishiyama
Förderung
- MEXT | Japan Society for the Promotion of Science (JSPS)
Zitieren
APA
Nagata, K., Ando, D., Ashikari, T., Ito, K., Miura, R., Fujigaki, I., Goto, Y., Ando, M., Ito, N., Kawazoe, H., Iizuka, Y., Inoue, M., Yashiro, T., Hachisu, M., Kasakura, K., & Nishiyama, C. (2024). Butyrate, Valerate, and Niacin Ameliorate Anaphylaxis by Suppressing IgE-Dependent Mast Cell Activation: Roles of GPR109A, PGE2, and Epigenetic Regulation. The Journal of Immunology. https://doi.org/10.4049/jimmunol.2300188
Vancouver
Nagata K, Ando D, Ashikari T, Ito K, Miura R, Fujigaki I, et al. Butyrate, Valerate, and Niacin Ameliorate Anaphylaxis by Suppressing IgE-Dependent Mast Cell Activation: Roles of GPR109A, PGE2, and Epigenetic Regulation. The Journal of Immunology. 2024. doi:10.4049/jimmunol.2300188
BibTeX
@article{Nagata2024,
author = {Nagata, Kazuki and Ando, Daisuke and Ashikari, Tsubasa and Ito, Kandai and Miura, Ryosuke and Fujigaki, Izumi and Goto, Yuki and Ando, Miki and Ito, Naoto and Kawazoe, Hibiki and Iizuka, Yuki and Inoue, Mariko and Yashiro, Takuya and Hachisu, Masakazu and Kasakura, Kazumi and Nishiyama, Chiharu},
title = {Butyrate, Valerate, and Niacin Ameliorate Anaphylaxis by Suppressing IgE-Dependent Mast Cell Activation: Roles of GPR109A, PGE2, and Epigenetic Regulation},
journal = {The Journal of Immunology},
year = {2024},
doi = {10.4049/jimmunol.2300188}
}
EUVIMED